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Background
It was recently hypothesized that the lentiviral reservoir in central memory (T CM ) and transitional memory (T TM ) CD4+ cells could be restricted by new therapies targeting pathways downstream of homeostatic proliferation or pathways associated with "stem cell-ness", such as those developed for the treatment of leukemias. Gar1041 is one such epigenetic drug adopted in the experimental treatment of certain types of leukemia.
Methods
SIVmac251-infected primates with viral loads stably suppressed by ART (tenofovir/emtricitabine/raltegravir) were administered for two months: Gar1041 twice daily (a starting dose of 1.5g in the first week followed by 2g in the remaining period). ART was continued during Gar1041 treatment. Proviral DNA was quantitated using a Taqman real-time PCR.
Results
The proviral DNA content of PBMCs, which had shown no significant changes during 54 days of treatment with ART alone (p >0.05), fell below the level of detection (2 copies/10 6 cells) in all study subjects within one month of Gar1041 treatment (p <0.05; Bonferroni's test following significant [p=0.0003] repeated measures ANOVA). No significant changes were noticed in a control group treated with ART alone (p=0.49). The decrease in proviral DNA was associated with a significant (p=0.0156) decrease in the proportions of the T CM CD4+ cell subpopulation in peripheral blood. However, both proviral DNA and the proportions of T CM CD4+ rebound after two months of therapy.
Conclusions
The present study furnishes proof of concept that pharmacological strategies may impact on the proviral DNA reservoir. However, the renewal of the phenotype T CM compartment, associated with the reconstitution of proviral DNA in peripheral blood from an as yet unidentified reservoir, will require integration with other experimental approaches. 
